Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

51.06 +5.11 (+11.12%)

Streaming Delayed Price Updated: 9:36 AM EST, Jan 7, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	414,213
Open	51.24
Bid (Size)	50.96 (100)
Ask (Size)	51.23 (100)
Prev. Close	45.95
Today's Range	49.72 - 51.98
52wk Range	24.10 - 57.99
Shares Outstanding	54,026,103
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

January 06, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock

January 05, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+9.3%	+9.3%
1 Month	+7.7%	+7.7%
3 Month	+20.1%	+20.1%
6 Month	+73.9%	+73.9%
1 Year	+1.1%	+1.1%

More News

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗

January 05, 2026

Via Stocktwits

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Wondering what's happening in today's pre-market session? ↗

January 05, 2026

Via Chartmill

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

January 05, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

January 04, 2026

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference

December 18, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

December 11, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 10, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors

December 03, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Via The Motley Fool

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

November 20, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Why Crinetics Pharmaceuticals Stock Was Sliding on Friday ↗

November 07, 2025

Via The Motley Fool

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Emerges as a Technical Breakout Candidate ↗

November 07, 2025

Via Chartmill

Crinetics Pharmaceuticals (NASDAQ:CRNX) Reports Q3 2025 Earnings Miss ↗

November 06, 2025

Via Chartmill

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 06, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

October 23, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 13, 2025

Via Benzinga

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 06, 2025

From Crinetics Pharmaceuticals, Inc.

Via GlobeNewswire

Is Crinetics Pharmaceuticals Stock a Buy? ↗

September 28, 2025

Via The Motley Fool

FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder ↗

September 26, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 26, 2025

Via Benzinga

Frequently Asked Questions

Is Crinetics Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Crinetics Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Crinetics Pharmaceuticals, Inc. - Common Stock trade on?

Crinetics Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Crinetics Pharmaceuticals, Inc. - Common Stock is CRNX on the Nasdaq Stock Market

What is the current price of Crinetics Pharmaceuticals, Inc. - Common Stock?

The current price of Crinetics Pharmaceuticals, Inc. - Common Stock is 51.06

When was Crinetics Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Crinetics Pharmaceuticals, Inc. - Common Stock was at 01/07/26 09:36 AM ET

What is the market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Crinetics Pharmaceuticals, Inc. - Common Stock is 2.76B

How many shares of Crinetics Pharmaceuticals, Inc. - Common Stock are outstanding?

Crinetics Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.